Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Helicobacter
; 29(1): e13040, 2024.
Article
em En
| MEDLINE
| ID: mdl-37983865
ABSTRACT
BACKGROUND AND OBJECTIVE:
Recently, vonoprazan-amoxicillin (VA) dual therapy has been reported as a promising approach for Helicobacter pylori (H. pylori) eradication. However, the effects of VA therapy versus bismuth-containing quadruple therapy (BQT) on H. pylori eradication remains unclear. The objective of this meta-analysis was to compare the effects of VA dual therapy with BQT for H. pylori eradication.METHODS:
A comprehensive search of the literature was conducted from the beginning to September 2023, utilizing PubMed, Embase, the Cochrane Library and Web of Science database. A random-effects model was used to perform a meta-analysis to determine the pooled relative risk (RR) with 95% confidence intervals (CIs). Moreover, trial sequential analysis (TSA) was conducted to evaluate the conclusiveness of the H. pylori eradication rate.RESULTS:
Six randomized controlled trials (RCTs) with 1233 patients were included. The VA therapy has similar eradication rate (ITTanalysis:
87% vs. 85.7%, RR = 1.01, 95% CI 0.93-1.09, p = 0.84; PPanalysis:
92.5% vs. 93.2%, RR = 1.00, 95% CI 0.94-1.06, p = 0.97) and compliance (RR = 1.01, 95% CI 0.99-1.03, p = 0.32) compared to BQT. The VA therapy group had a significantly lower incidence of total adverse events than the BQT group (16.3% vs. 40.0%, RR = 0.45, 95% CI 0.37-0.55, p < 0.00001). The TSA result showed that the effect was conclusive.CONCLUSIONS:
Current evidence indicated that VA therapy is just as successful as BQT in eliminating H. pylori, yet it has fewer adverse events and similar compliance.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Bismuto
/
Helicobacter pylori
/
Infecções por Helicobacter
/
Amoxicilina
/
Antibacterianos
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Helicobacter
Assunto da revista:
BACTERIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China